OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Rubric Capital Management LP

Rubric Capital Management LP boosted its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 800.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,422,304 shares of the biotechnology company’s stock after acquiring an additional 39,486,490 shares during the quarter. OPKO Health accounts for approximately 1.5% of Rubric Capital Management LP’s investment portfolio, making the stock its 27th biggest position. Rubric Capital Management LP owned 6.37% of OPKO Health worth $55,528,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of OPK. Y.D. More Investments Ltd acquired a new stake in shares of OPKO Health during the 2nd quarter worth about $1,840,000. Lazard Asset Management LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth about $258,000. BNP Paribas Financial Markets raised its position in shares of OPKO Health by 349.8% during the 4th quarter. BNP Paribas Financial Markets now owns 271,872 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 211,429 shares in the last quarter. AWM Investment Company Inc. raised its position in shares of OPKO Health by 18.2% during the 1st quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock worth $1,560,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Tidal Investments LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth about $239,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at OPKO Health

In other news, major shareholder Opko Health, Inc. sold 50,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $26.63, for a total transaction of $1,331,500.00. Following the completion of the sale, the insider now directly owns 3,508,603 shares of the company’s stock, valued at approximately $93,434,097.89. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 736,644 shares of company stock valued at $23,874,134. 47.26% of the stock is owned by corporate insiders.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.48 on Friday. OPKO Health, Inc. has a 1-year low of $0.85 and a 1-year high of $1.75. The business has a 50-day moving average of $1.52 and a 200-day moving average of $1.33. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.63 and a quick ratio of 1.36. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -4.23 and a beta of 1.64.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.08. The firm had revenue of $182.20 million for the quarter, compared to analysts’ expectations of $184.70 million. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. OPKO Health’s revenue for the quarter was down 31.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. On average, equities analysts anticipate that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday. StockNews.com upgraded OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Piper Sandler restated an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Tuesday.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.